HIV-associated dyslipidaemia: pathogenesis and treatment (Q37018213)

17 August 2017

1 reference

title

HIV-associated dyslipidaemia: pathogenesis and treatment (English)

1 reference

17 August 2017

0 references

0 references

1 reference

Robert A Hegele

0 references

author name string

Jisun Oh

series ordinal

1 reference

17 August 2017

publication date

1 December 2007

1 reference

Lancet Infectious Diseases

17 August 2017

published in

1 reference

17 August 2017

1 reference

17 August 2017

1 reference

17 August 2017

page(s)

787-796

1 reference

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Hyperlipidemia associated with HIV protease inhibitor use: pathophysiology, prevalence, risk factors and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Combination antiretroviral therapy and the risk of myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Class of Antiretroviral Drugs and the Risk of Myocardial Infarction

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Plasma lipids in HIV-infected patients: a prospective study in 95 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Protease inhibitor-based HAART, HDL, and CHD-risk in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

HIV infection and high-density lipoprotein: the effect of the disease vs the effect of treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Effects of rosiglitazone and metformin on postprandial paraoxonase-1 and monocyte chemoattractant protein-1 in human immunodeficiency virus-infected patients with lipodystrophy.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Plasma platelet-activating factor acetylhydrolase activity in human immunodeficiency virus infection and the acquired immunodeficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Apolipoprotein A and biological half-life of prostaglandin I2 in HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Molecular regulation of HDL metabolism and function: implications for novel therapies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Human immunodeficiency virus impairs reverse cholesterol transport from macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Interferon alpha induces disorder of lipid metabolism by lowering postheparin lipases and cholesteryl ester transfer protein activities in patients with chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Mechanism of highly active anti-retroviral therapy-induced hyperlipidemia in HIV-infected individuals

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

In treatment-naïve and antiretroviral-treated subjects with HIV, reduced plasma adiponectin is associated with a reduced fractional clearance rate of VLDL, IDL and LDL apolipoprotein B-100.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Tumor necrosis factor alpha is associated with insulin-mediated suppression of free fatty acids and net lipid oxidation in HIV-infected patients with lipodystrophy.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Hypertriglyceridemia in the acquired immunodeficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Circulating interferon-alpha levels and hypertriglyceridemia in the acquired immunodeficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Impact of HIV and highly active antiretroviral therapy on leukocyte adhesion molecules, arterial inflammation, dyslipidemia, and atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Protease Inhibitor-Associated Dyslipidemia in HIV-Infected Patients Is Strongly Influenced by the APOA5-1131T->C Gene Variation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Influence of protease inhibitor therapy on lipoprotein metabolism.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

High-density lipoprotein cholesterol is low in HIV-infected patients with lipodystrophic fat expansions: implications for pathogenesis of fat redistribution

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Sex differences in HAART-associated dyslipidaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Impact of HIV infection and HAART on serum lipids in men.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

High plasma lipoprotein (a) in HIV-positive patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Association of lipoprotein(a), prostaglandin I(2)--synthesis stimulating plasma factor, biological half-life of prostaglandin I(2)and high-density lipoproteins in HIV-1 infection of different stages

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Antiretroviral therapy in HIV-positive women is associated with increased apolipoproteins and total cholesterol.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Fibrates or statins and lipid plasma levels in 245 patients treated with highly active antiretroviral therapy. Aquitaine Cohort, France, 1999-2001.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Human plasmatic apolipoprotein H binds human immunodeficiency virus type 1 and type 2 proteins

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Antiretroviral treatment reduces very-low-density lipoprotein and intermediate-density lipoprotein apolipoprotein B fractional catabolic rate in human immunodeficiency virus-infected patients with mild dyslipidemia.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Severely dysregulated disposal of postprandial triacylglycerols exacerbates hypertriacylglycerolemia in HIV lipodystrophy syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Alterations in liver, muscle, and adipose tissue insulin sensitivity in men with HIV infection and dyslipidemia.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

In vivo evidence of impaired peripheral fatty acid trapping in patients with human immunodeficiency virus-associated lipodystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Indinavir inhibits sterol-regulatory element-binding protein-1c-dependent lipoprotein lipase and fatty acid synthase gene activations

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Increased intramyocellular lipid accumulation in HIV-infected women with fat redistribution

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Relative effects of insulin resistance and protease inhibitor treatment on lipid and lipoprotein metabolism in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

LDL-receptors expression in HIV-infected patients: relations to antiretroviral therapy, hormonal status, and presence of lipodystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Alterations in lipid kinetics in men with HIV-dyslipidemia.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Anti-HIV drugs and the mitochondria

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Mitochondrial involvement in antiretroviral therapy-related lipodystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

LRP: a new adhesion molecule for endothelial and smooth muscle cells

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Lipoprotein lipase mediates the uptake of glycated LDL in fibroblasts, endothelial cells, and macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Associations among race/ethnicity, ApoC-III genotypes, and lipids in HIV-1-infected individuals on antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Monogenic dyslipidemias: window on determinants of plasma lipoprotein metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Hyperlipidaemia in patients with HIV-1 infection receiving highly active antiretroviral therapy: epidemiology, pathogenesis, clinical course and management

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Guidelines for the Evaluation and Management of Dyslipidemia in Human Immunodeficiency Virus (HIV)-Infected Adults Receiving Antiretroviral Therapy: Recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Acute pancreatitis associated with different combination therapies in patients infected with human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Dyslipidemia of the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Carbohydrate restriction improves the features of Metabolic Syndrome. Metabolic Syndrome may be defined by the response to carbohydrate restriction

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Resistance exercise training reduces hypertriglyceridemia in HIV-infected men treated with antiviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Atazanavir--a once-daily HIV protease inhibitor that does not cause dyslipidemia in newly treated patients: results from two randomized clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Impact of dyslipidemia associated with Highly Active Antiretroviral Therapy (HAART) on cardiovascular risk and life expectancy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug r

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Impact of nevirapine on lipid metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

The long-term pharmacokinetics and safety of adding low-dose ritonavir to a nelfinavir 1,250 mg twice-daily regimen in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Long-term and concentration-dependent beneficial effect of efavirenz on HDL-cholesterol in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Effect of delavirdine on plasma lipids and lipoproteins in patients receiving antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Plasma lipid concentrations after 1.5 years of exposure to nevirapine or efavirenz together with stavudine and lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovir

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Influence of pravastatin on carotid artery structure and function in dyslipidemic HIV-infected patients receiving antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Pravastatin in HIV-infected patients treated with protease inhibitors: a placebo-controlled randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Pravastatin does not alter protease inhibitor exposure or virologic efficacy during a 24-week period of therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Lipid lowering therapy with fluvastatin and pravastatin in patients with HIV infection and antiretroviral therapy: comparison of efficacy and interaction with indinavir

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Statin compounds reduce human immunodeficiency virus type 1 replication by preventing the interaction between virion-associated host intercellular adhesion molecule 1 and its natural cell surface ligand LFA-1.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Evaluation of the anti-HIV activity of statins

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Rosuvastatin for the treatment of hyperlipidaemia in HIV-infected patients receiving protease inhibitors: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Rosuvastatin: a highly potent statin for the prevention and management of coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Effects of statins on endothelial function and lipid profile in HIV infected persons receiving protease inhibitor-containing anti-retroviral combination therapy: a randomised double blind crossover trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Effects of pravastatin on lipoproteins and endothelial function in patients receiving human immunodeficiency virus protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Long-term metabolic consequences of switching from protease inhibitors to efavirenz in therapy for human immunodeficiency virus-infected patients with lipoatrophy.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Simvastatin-induced rhabdomyolysis in an HIV-infected patient with coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Rhabdomyolysis due to probable interaction between simvastatin and ritonavir

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Simvastatin-nelfinavir interaction implicated in rhabdomyolysis and death

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Rhabdomyolysis after simvastatin therapy in an HIV-infected patient with chronic renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Rhabdomyolysis with acute renal failure probably related to the interaction of atorvastatin and delavirdine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Drug-induced rhabdomyolysis after concomitant use of clarithromycin, atorvastatin, and lopinavir/ritonavir in a patient with HIV.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men--a randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

A randomized, double-blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertriglyceridaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Lipid lowering effects of statins and fibrates in the management of HIV dyslipidemias associated with antiretroviral therapy in HIV clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Use of fibrates in the management of hyperlipidemia in HIV-infected patients receiving HAART.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Gemfibrozil effectively lowers protease inhibitor-associated hypertriglyceridemia in HIV-1-positive patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Fenofibrate improves the atherogenic lipid profile and enhances LDL resistance to oxidation in HIV-positive adults

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Apoprotein c-III and E-containing lipoparticles are markedly increased in HIV-infected patients treated with protease inhibitors: association with the development of lipodystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Improvement in highly active antiretroviral therapy-induced metabolic syndrome by treatment with pioglitazone but not with fenofibrate: a 2 x 2 factorial, randomized, double-blinded, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Combination therapy with fenofibrate and rosiglitazone paradoxically lowers serum HDL cholesterol

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Management of protease inhibitor-associated hyperlipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Fenofibrate is effective in treating hypertriglyceridemia associated with HIV lipodystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Heart positive: design of a randomized controlled clinical trial of intensive lifestyle intervention, niacin and fenofibrate for HIV lipodystrophy/dyslipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Use of fenofibrate in the management of protease inhibitor-associated lipid abnormalities

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Bezafibrate-induced improvement in glucose uptake and endothelial function in protease inhibitor-associated insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

NPC1L1: evolution from pharmacological target to physiological sterol transporter

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Ezetimibe effectively decreases LDL-cholesterol in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Characterization of a new circulating recombinant form comprising HIV-1 subtypes C and B in southern Brazil.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Effects of nonstatin lipid drug therapy on high-density lipoprotein metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Niacin in HIV-infected individuals with hyperlipidemia receiving potent antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Improved triglycerides and insulin sensitivity with 3 months of acipimox in human immunodeficiency virus-infected patients with hypertriglyceridemia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Randomized study of the safety and efficacy of fish oil (omega-3 fatty acid) supplementation with dietary and exercise counseling for the treatment of antiretroviral therapy-associated hypertriglyceridemia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Reduction in Triglyceride Level With N-3 Polyunsaturated Fatty Acids in HIV-Infected Patients Taking Potent Antiretroviral Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Polyunsaturated ethyl esters of n-3 fatty acids in HIV-infected patients with moderate hypertriglyceridemia: comparison with dietary and lifestyle changes, and fibrate therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

Lipid-lowering and anti-inflammatory effects of tetradecylthioacetic acid in HIV-infected patients on highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

A pilot study of the safety and efficacy of cholestin in treating HIV-related dyslipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

L-Carnitine for the treatment of highly active antiretroviral therapy-related hypertriglyceridemia in HIV-infected adults

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970287-6

7 January 2021

10.1016/S1473-3099(07)70287-6

Identifiers

DOI

1 reference

17 August 2017

1 reference